Illumina, Inc. logo ILMN - Illumina, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
1
BUY 25
HOLD 18
SELL 6
STRONG
SELL
0
| PRICE TARGET: $156.27 DETAILS
HIGH: $200.00
LOW: $122.00
MEDIAN: $155.00
CONSENSUS: $156.27
DOWNSIDE: 16.79%

Stock News

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies SAN DIEGO, June 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights.

Jun 08, 2026 05:15 AM prnewswire.com
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency.

May 28, 2026 08:30 AM prnewswire.com
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD market SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research.

May 28, 2026 05:15 AM prnewswire.com

Price Targets